Chronix Biomedical appoints new chairman
This article was originally published in Clinica
Chronix Biomedical, a company developing serum DNA-based blood tests to detect and manage cancer, has made Paul Freiman chairman of the board. Mr Freiman has over 30 years' experience in the pharmaceutical and biotech industry, including as CEO of Syntex and Neurobiological Technologies. He also serves on the board of Penwest Pharmaceuticals, Otsuka America Pharmaceuticals and NeoPharm. San Jose, California-based Chronix is developing blood tests that analyse DNA released into the blood by damaged and dying cells. They are designed to detect cancer at its earliest stages and track patients' responses to treatment. The company is currently advancing its technology through clinical validation towards commercialisation, and is seeking partners for further development.